|  |  |  |
| --- | --- | --- |
|  | Case 1 (dedifferentiated liposarcoma) | Case 2 (myxofibrosarcoma) |
| Genomic alterations | *CDK4* amplification  *ERBB2* G776A  *ERBB3* amplification *AURKA* amplification  *MDM2* amplification  *CXCR4* M1? – subclonal  *FRS2* amplification  *GNAS* amplification *HMGA2* HMGA2-TSPAN31 fusion  *ZNF217* amplification | *NF1* R2637  *CDKN2A/B* loss  *CEBPA* loss  *TP53* H193L |
| Microsatellite status | MS-stable | Not available |
| PD-L1 status | 0% | 0% |
| Tumor mutational burden | Intermediate (7 mutations/Mb) | Not available |

Supplemental Table 1. FoundationOne® panel for two patients. PD-L1 testing performed with immunohistochemistry using Dako 22C3 pharmDx™ assay. MS, microsatelite. Mb, megabase.